Table 2 Histological and genetic characteristics of the patients treated with a pemetrexed-containing therapy
Total (n = 314) | Good responders (n = 92) | Poor responders (n = 222) | P-value | |
|---|---|---|---|---|
Histology | 0.810 | |||
Adenocarcinoma | 285 (90.8) | 83 (90.2) | 202 (91.0) | |
Large cell carcinoma | 5 (1.6) | 2 (2.2) | 3 (1.4) | |
NSCLC-NOS | 24 (7.6) | 7 (7.6) | 17 (7.7) | |
Subtype (n = 57)* | 57 | 24 | 33 | 0.368 |
Mucinous | 22 (38.6) | 10 (41.7) | 12 (36.4) | |
Acinar | 13 (22.8) | 7 (29.2) | 6 (18.2) | |
Papillary | 13 (22.8) | 4 (16.7) | 9 (27.3) | |
Signet-ring | 5 (8.8) | 3 (12.5) | 2 (6.1) | |
Solid | 4 (7.0) | 0 | 4 (12.1) | |
Differentiation (n = 220) | 220 | 63 | 157 | 0.001 |
Well-differentiated | 18 (8.2) | 12 (19.0) | 6 (3.8) | |
Moderately-differentiated | 115 (52.3) | 29 (46.0) | 86 (54.8) | |
Poorly-differentiated | 87 (39.5) | 22 (34.9) | 65 (41.4) | |
TTF-1 expression (n = 151) | 125 (82.8) | 35 (94.6) | 90 (78.9) | 0.028 |
Gene mutation (n = 239) | 239 | 72 | 167 | |
EGFR mutation | 89 (37.2) | 12 (16.7) | 77 (46.1) | <0.001 |
ALK translocation | 23 (9.6) | 16 (22.2) | 7 (4.2) | <0.001 |
KRAS mutation | 5 (2.1) | 0 | 5 (3.0) | 0.326 |
Wild-type for EGFR/ALK/KRAS | 122 (51.0) | 44 (61.1) | 78 (46.7) | 0.041 |